Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NVO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NVO and 80,000+ other tickers.
See exactly how NVO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NVO and 80,000+ other tickers.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging…
Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market.
Novo Nordisk (NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge
Novo Nordisk A/S receives a Sell rating due to falling profits, weak revenue growth, and operational missteps despite its blockbuster semaglutide franchise. NVO's 2026 guidance signals flat to negative sales and operating profit growth, contrasting sharply with Eli Lilly's robust growth trajectory and diversified pipeline. Patent expiries, manufacturing setbacks, and pipeline disappointments undermine NVO's first-mover advantage in obesity and diabetes, while competition intensifies.
Novo Nordisk recently experienced a clinical setback. Despite financial results mostly in line with expectations, one product fell short.
Novo Nordisk A/S delivered a strong Q2, beating revenue by 10% and EPS by over 20%, yet shares dipped post-earnings. NVO's adjusted revenues rose 7% year-over-year, driven by international and obesity care growth, despite US pricing headwinds and competition. Operating profit grew 11% due to cost reductions, and guidance was raised for the second time this year, signaling potential conservatism.